# Immunomodulator Agents for Systemic Inflammatory Disease 

[Criteria Document](https://mygainwell-my.sharepoint.com/:w:/g/personal/kaelyn_dobbins_gainwelltechnologies_com/Ec458Le0AM5Gk6ORoP5aSRIBs-QSmKksE4fPAeeOkeqKVg?e=Vdgu2G){:target="_blank" rel="noopener}

|||
| ---------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| Criteria 1 | Preferred with PA- Adbry, Enbrel, Humira, Kineret, Otezla, Xeljanz IR                                                                                                                |
| Criteria 2 | Preferred with ST- Taltz                                                                                                                                                             |
| Criteria 3 | Non-Preferred- Actemra, Amjevita, Cibinqo, Cimzia, Cosentyx, Ilumya, Kevzara, Olumiant, Orencia, Rinvoq, Siliq, Simponi, Skyrizi, Sotyktu, Stelara, Tremfya, Xeljanz Sol, Xeljanz XR |
| Criteria 4 | Dupixent PA                                                                                                                                                                          |

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Immunomodulator Agents: Systemic Inflammatory Disease</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Preferred Products with PA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>ADBRY</td>
<td>082945</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>ENBREL</td>
<td>040869</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>ENBREL</td>
<td>058214</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>ENBREL</td>
<td>061938</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>ENBREL</td>
<td>062624</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>ENBREL</td>
<td>077783</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>ENBREL</td>
<td>081339</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>HUMIRA</td>
<td>051599</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>HUMIRA</td>
<td>061205</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>HUMIRA</td>
<td>077469</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>HUMIRA</td>
<td>077470</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>HUMIRA</td>
<td>077767</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>HUMIRA</td>
<td>077870</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>HUMIRA</td>
<td>078347</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>HUMIRA</td>
<td>078348</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>HUMIRA</td>
<td>078360</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>HUMIRA</td>
<td>078672</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>KINERET</td>
<td>048899</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>OTEZLA</td>
<td>072075</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>OTEZLA</td>
<td>073370</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>XELJANZ IR</td>
<td>070233</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>XELJANZ IR</td>
<td>078538</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Sequence Number </strong></td>
<td><strong>Question ID </strong></td>
<td><strong>Default Next Question ID </strong></td>
<td><strong>Question Type </strong></td>
<td><strong>Question Text </strong></td>
<td><strong>Choice Text </strong></td>
<td><strong>Next Question ID </strong></td>
</tr>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> with at least <span class="underline">two applicable</span> first-line drugs indicated for diagnosis?</p>
<p>If yes, please submit documentation of the trialed drugs, dosages, dates, and durations.</p></td>
<td>Y </td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of the requested loading and maintenance dosing, if applicable?</p>
<p>Please note: Authorization of dosing regimens (loading/maintenance) will be based upon diagnosis.</p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select  </td>
<td>Does the patient have a current, active infection? </td>
<td>Y    </td>
<td>1235</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1003</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select</td>
<td>Is a negative tuberculosis (TB) test prior to initiation of biologic therapy required for the requested agent?</td>
<td>Y    </td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1005</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1004</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of a negative tuberculosis (TB) test prior to initiation of biologic therapy? </td>
<td>Y    </td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>8</td>
<td>1005</td>
<td></td>
<td>Select </td>
<td>What is the patient’s diagnosis?  </td>
<td>Alopecia areata</td>
<td>4000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Atopic dermatitis </td>
<td> 5000 </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Plaque psoriasis </td>
<td> 6000 </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ulcerative colitis </td>
<td> 7000 </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other </td>
<td> 1006</td>
</tr>
<tr class="even">
<td>9</td>
<td>1006</td>
<td></td>
<td>Free Text</td>
<td>Please provide the patient’s diagnosis.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="odd">
<td>10</td>
<td>4000</td>
<td></td>
<td>Select</td>
<td>Is the medication being prescribed by or in consultation with a specialist (i.e., dermatologist, rheumatologist)? </td>
<td>Y </td>
<td> 4001 </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>11</td>
<td>4001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of an inadequate clinical response of at least 90 days with a topical steroid?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y</td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>12</td>
<td> 5000 </td>
<td> </td>
<td>Select  and Free Text</td>
<td><p>Does the patient have at least 10% body surface area (BSA) involvement with two of the following: topical corticosteroids or topical calcineurin inhibitors [e.g., Elidel]?</p>
<p>If yes, please submit the medication trials and dates.  </p></td>
<td>Y </td>
<td> END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td> 5001</td>
</tr>
<tr class="odd">
<td>13</td>
<td>5001</td>
<td></td>
<td>Select</td>
<td>Is the patient’s atopic dermatitis severe and involves greater than 25% BSA?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>14</td>
<td> 6000 </td>
<td> </td>
<td> Select </td>
<td><p>Has the patient had an inadequate clinical response to at least <span class="underline">90 days</span> of phototherapy?   </p>
<p> </p></td>
<td>Y </td>
<td> END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>15</td>
<td> 7000 </td>
<td> </td>
<td> Select  </td>
<td><p>Has the patient had an inadequate clinical response after 90 days with one TNF inhibitor? </p>
<p>Please note: further TNF inhibitors will not be authorized.</p></td>
<td>Y </td>
<td>1235 </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>16</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td>Y    </td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>17</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: Initial: 90 days; Subsequent: 365 days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |

**  
**

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Immunomodulator Agents: Systemic Inflammatory Disease</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Preferred Step Therapy Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>TALTZ</td>
<td>075731</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TALTZ</td>
<td>075732</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> with at least <span class="underline">two applicable</span> first-line drugs indicated for diagnosis?</p>
<p>If yes, please submit documentation of the trialed drugs, dosages, dates, and durations.</p></td>
<td>Y </td>
<td>1001</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of the requested loading and maintenance dosing, if applicable?</p>
<p>Please note: Authorization of dosing regimens (loading/maintenance) will be based upon diagnosis.</p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select  </td>
<td>Does the patient have a current, active infection? </td>
<td>Y    </td>
<td>1235</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1003</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select</td>
<td>Is a negative tuberculosis (TB) test prior to initiation of biologic therapy required for the requested agent?</td>
<td>Y    </td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1005</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1004</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of a negative tuberculosis (TB) test prior to initiation of biologic therapy? </td>
<td>Y    </td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>8</td>
<td>1005</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least 90 days with at least one preferred TNF inhibitor indicated for diagnosis?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y</td>
<td>1007</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1006</td>
</tr>
<tr class="odd">
<td>9</td>
<td>1006</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y</td>
<td>1007</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1236</td>
</tr>
<tr class="odd">
<td>10</td>
<td>1007</td>
<td></td>
<td>Select </td>
<td>What is the patient’s diagnosis?  </td>
<td>Alopecia areata</td>
<td>4000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Atopic dermatitis </td>
<td> 5000 </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Plaque psoriasis </td>
<td> 6000 </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ulcerative colitis </td>
<td>7000</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other </td>
<td> 1008</td>
</tr>
<tr class="even">
<td>11</td>
<td>1008</td>
<td></td>
<td>Free Text</td>
<td>Please provide the patient’s diagnosis.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="odd">
<td>12</td>
<td>4000</td>
<td></td>
<td>Select</td>
<td>Is the medication being prescribed by or in consultation with a specialist (i.e., dermatologist, rheumatologist)? </td>
<td>Y </td>
<td>4001 </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>13</td>
<td>4001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of an inadequate clinical response of at least 90 days with a topical steroid?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y</td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>14</td>
<td> 5000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Does the patient have at least 10% body surface area (BSA) involvement with two of the following: topical corticosteroids or topical calcineurin inhibitors [e.g., Elidel]?</p>
<p>If yes, please submit the medication trials and dates.  </p></td>
<td>Y </td>
<td> END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td> 5001</td>
</tr>
<tr class="odd">
<td>15</td>
<td>5001</td>
<td></td>
<td>Select</td>
<td>Is the patient’s atopic dermatitis severe and involves greater than 25% BSA?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>16</td>
<td> 6000 </td>
<td> </td>
<td> Select </td>
<td>Has the patient had an inadequate clinical response to at least <span class="underline">90 days</span> of phototherapy?   </td>
<td>Y </td>
<td> END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td> 1235 </td>
</tr>
<tr class="odd">
<td>17</td>
<td> 7000 </td>
<td> </td>
<td> Select  </td>
<td><p>Has the patient had an inadequate clinical response after 90 days with one TNF inhibitor? </p>
<p>Please note: further TNF inhibitors will not be authorized.</p></td>
<td>Y </td>
<td>1235 </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>18</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td>Y    </td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>19</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>20</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: Initial: 90 days; Subsequent: 365 days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |

**  
**

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Immunomodulator Agents: Systemic Inflammatory Disease</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred Products</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>ACTEMRA</td>
<td>071590</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>ACTEMRA</td>
<td>078707</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>AMJEVITA</td>
<td>076794</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>AMJEVITA</td>
<td>076834</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>AMJEVITA</td>
<td>076836</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>AMJEVITA</td>
<td>084656</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>CIBINQO</td>
<td>082989</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>CIBINQO</td>
<td>082990</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>CIBINQO</td>
<td>082991</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>CIMZIA</td>
<td>063903</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>CIMZIA</td>
<td>065189</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>COSENTYX</td>
<td>073394</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>COSENTYX</td>
<td>073395</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>COSETNYX</td>
<td>082340</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>ILUMYA</td>
<td>078258</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>KEVZARA</td>
<td>077264</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>KEVZARA</td>
<td>077265</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>KEVZARA</td>
<td>078046</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>KEVZARA</td>
<td>078047</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>OLUMIANT</td>
<td>077445</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>OLUMIANT</td>
<td>077446</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>OLUMIANT</td>
<td>080389</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>ORENCIA</td>
<td>067681</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>ORENCIA</td>
<td>076265</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>ORENCIA</td>
<td>077399</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>ORENCIA</td>
<td>077400</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>RINVOQ</td>
<td>080125</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>RINVOQ</td>
<td>082927</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>RINVOQ</td>
<td>083196</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>SILIQ</td>
<td>077139</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>SIMPONI</td>
<td>065113</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>SIMPONI</td>
<td>065114</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>SIMPONI</td>
<td>071017</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>SIMPONI</td>
<td>071262</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>SOTYKTU</td>
<td>083817</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>SKYRIZI</td>
<td>079675</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>SKYRIZI</td>
<td>082261</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>SKYRIZI</td>
<td>082262</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>SKYRIZI</td>
<td>083492</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>STELARA</td>
<td>064967</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>STELARA</td>
<td>065993</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>STELARA</td>
<td>065994</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>TREMFYA</td>
<td>077565</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>TREMFYA</td>
<td>079520</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>XELJANZ SOL, XR</td>
<td>075641</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td></td>
<td>XELJANZ SOL, XR</td>
<td>080628</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td></td>
<td>XELJANZ SOL, XR</td>
<td>081537</td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><strong>Sequence Number </strong></td>
<td><strong>Question ID </strong></td>
<td><strong>Default Next Question ID </strong></td>
<td><strong>Question Type </strong></td>
<td><strong>Question Text </strong></td>
<td><strong>Choice Text </strong></td>
<td><strong>Next Question ID </strong></td>
</tr>
<tr class="even">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="even">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> with at least <span class="underline">two applicable</span> first-line drugs indicated for diagnosis?</p>
<p>If yes, please submit documentation of the trialed drugs, dosages, dates, and durations.</p></td>
<td>Y </td>
<td>1001</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235</td>
</tr>
<tr class="even">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of the requested loading and maintenance dosing, if applicable?</p>
<p>Please note: Authorization of dosing regimens (loading/maintenance) will be based upon diagnosis.</p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1235</td>
</tr>
<tr class="even">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select  </td>
<td>Does the patient have a current, active infection? </td>
<td>Y    </td>
<td>1235</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1003</td>
</tr>
<tr class="even">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select</td>
<td>Is a negative tuberculosis (TB) test prior to initiation of biologic therapy required for the requested agent?</td>
<td>Y    </td>
<td>1004</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1005</td>
</tr>
<tr class="even">
<td>7</td>
<td>1004</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of a negative tuberculosis (TB) test prior to initiation of biologic therapy? </td>
<td>Y    </td>
<td>1005</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>8</td>
<td>1005</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> with at least <span class="underline">two preferred</span> drugs, if indicated for diagnosis?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y</td>
<td>1007</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1006</td>
</tr>
<tr class="even">
<td>9</td>
<td>1006</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y</td>
<td>1007</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1236</td>
</tr>
<tr class="even">
<td>10</td>
<td>1007</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1008</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1009</td>
</tr>
<tr class="even">
<td>11</td>
<td>1008</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>1009</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>12</td>
<td>1009</td>
<td></td>
<td>Select </td>
<td>What is the patient’s diagnosis?  </td>
<td>Alopecia areata</td>
<td>4000</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Atopic dermatitis </td>
<td> 5000 </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Plaque psoriasis </td>
<td> 6000 </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ulcerative colitis </td>
<td> 7000 </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other </td>
<td> 1010</td>
</tr>
<tr class="odd">
<td>13</td>
<td>1010</td>
<td></td>
<td>Free Text</td>
<td>Please provide the patient’s diagnosis.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>14</td>
<td>4000</td>
<td></td>
<td>Select</td>
<td>Is the medication being prescribed by or in consultation with a specialist (i.e., dermatologist, rheumatologist)? </td>
<td>Y </td>
<td>4001 </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>15</td>
<td>4001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of an inadequate clinical response of at least 90 days with a topical steroid?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y</td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>16</td>
<td> 5000 </td>
<td> </td>
<td>Select  and Free Text</td>
<td><p>Does the patient have at least 10% body surface area (BSA) involvement with two of the following: topical corticosteroids or topical calcineurin inhibitors [e.g., Elidel]?</p>
<p>If yes, please submit the medication trials and dates.  </p></td>
<td>Y </td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td> 5001</td>
</tr>
<tr class="even">
<td>17</td>
<td>5001</td>
<td></td>
<td>Select</td>
<td>Is the patient’s atopic dermatitis severe and involves greater than 25% BSA?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="even">
<td>18</td>
<td> 6000 </td>
<td> </td>
<td> Select </td>
<td><p>Has the patient had an inadequate clinical response to at least <span class="underline">90 days</span> of phototherapy?   </p>
<p> </p></td>
<td>Y </td>
<td> END (Pending Manual Review) </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>19</td>
<td> 7000 </td>
<td> </td>
<td> Select  </td>
<td><p>Has the patient had an inadequate clinical response after 90 days with one TNF inhibitor? </p>
<p>Please note: further TNF inhibitors will not be authorized.</p></td>
<td>Y </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td>20</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td>Y    </td>
<td>END (Pendng Manual Review) </td>
</tr>
<tr class="odd">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="even">
<td>21</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="odd">
<td>22</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: Initial: 90 days; Subsequent: 365 days

| **Last Approved ** | 8/11/2023 |
| ------------------ | --------- |
| **Other**          |           |
